Legislators
Bills
Statements
Lobbying
Travel
Searching...- Lobbying
- Lobbying by Jazz Pharmaceuticals, Inc.
Lobbying Relationship
Bills mentioned
H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
Sponsor: Frank Pallone (D-N.J.)
H.R.1996: SAFE Banking Act of 2021
Sponsor: Ed Perlmutter (D-Colo.)
S.2860: Secure And Fair Enforcement Regulation Banking Act
Sponsor: Jeff Merkley (D-Ore.)
H.R.5539: ORPHAN Cures Act
Sponsor: John Joyce (R-Pa.)
S.3131: ORPHAN Cures Act
Sponsor: John Barrasso (R-Wyo.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
| Lobbyist | Covered positions? |
|---|---|
| Virginia McMillin | Health Policy Advisor - Senate Committee on Health, Education, Labor and Pensions; Staff member - Senate Committee on Health, Education, Labor and Pensions Special Assistant to the President (9/2018-12/2020); Health Policy Advisor, Senate Committee on HELP (1/2018-9/2019); Staff, Senate Committee on HELP (5/2012-1/2018) |
| Karas Gross | FDA - Associate Commissioner for Legislative Affairs (2019-20); House Rules Committee - Deputy Staff Director (2011-19); House Judiciary Committee - Deputy Parliamentarian (2008-11); House of Representatives - Sr. Legislative Assistant (2004-08) |
| Mark Bolton | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate